Ruxolitinib in Operable Head and Neck Cancer

Condition:   Head and Neck Squamous Cell Carcinoma
Intervention:   Drug: Ruxolitinib
Sponsors:   University of California, San Francisco;   Incyte Pharmaceuticals
Not yet recruiting - verified May 2017

http://ift.tt/2qlaDm3


http://ift.tt/2qlO7ct